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Acute high-altitude illness
To the Editor: It was delightful to see an article[1] about altitude 
illness in a recent issue of SAMJ, especially in view of the fact 
that over the years there have been many unnecessary deaths on 
Kilimanjaro due to climbers going up too high too fast. For this 
reason, prevention of altitude illness is indeed a very relevant topic 
for your local readership in Africa. The authors have rightly pointed 
out that ascending gradually is the best away to acclimatise to high 
altitude and not suffer from acute mountain sickness (AMS) and life-
threatening high-altitude cerebral oedema (HACE) and high-altitude 
pulmonary oedema (HAPE).
Unfortunately there are several misperceptions in the article, 
and I would like to focus on the use of acetazolamide. The authors 
do not seem to be clear about the fact that there is strong evidence 
for the role of acetazolamide in the prevention of AMS. In fact, the 
guideline[2] that they cite mentions this in no uncertain terms. Clearly 
for most trekkers it may be best not to take any drugs and trek up the 
mountain gradually, but in certain circumstances (for example in a 
trekker with a prior history of AMS) acetazolamide is certainly very 
useful chemoprophylaxis. This important fact about the usefulness 
of acetazolamide when necessary is not emphasised. In fact, the 
authors promptly note the uncommon side-effects of acetazolamide, 
including blurred vision, and later lump the most common side-effect 
(by far), which is a tingling and burning sensation in the fingers and 
toes, together with the relatively rare side-effects.
In addition, in the treatment of moderate AMS, where acetazolamide 
is clearly indicated with strong evidence for its effectiveness,[2] the 
authors bring up acetazolamide treatment almost as an afterthought.
They suggest acetazolamide for established HAPE, but in the 
setting of HAPE this diuretic may in fact cause more dehydration and 
hyperventilation and complicate the problem, and is not indicated. [2] 
In addition they suggest treatment of HAPE with dexamethasone, 
when there is no proof in the literature for this, and they also suggest 
simultaneously administering both nifedipine and sildenafil for 
HAPE, which many high-altitude doctors would frown upon.
Finally, it is probably true to say that if knowledgeable guides were 
to carry acetazolamide and dexamethasone on Kilimanjaro trips, lives 
could potentially be saved.
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Dr R Hofmeyr et al. respond: We note with pleasure that our recent 
article on acute high-altitude illness[1] has drawn significant attention, 
and are greatly encouraged by the discourse it has generated. 
We are grateful to Dr Basnyat for his expert engagement and 
acknowledgement of the challenges of managing acute altitude-
related illnesses (such as AMS, HACE and HAPE) in Africa. We 
regret, therefore, if the brevity of our article and its strong emphasis 
on safe acclimatisation practices and basic field management of 
altitude illness have left the misapprehension that we do not advocate 
the use of acetazolamide where indicated.
Rapid ascent to high altitudes by relative novices is not a uniquely 
African problem, nor is it limited to mountaineers.[2] However, African 
peaks (such as Kilimanjaro, Kenya, Stanley and Toubkal) very frequently 
feature short approaches with increased potential for high-risk ascent 
profiles.[3] The non-technical nature of many of these peaks allows many 
trekkers and climbers to ascend and descend rapidly enough to have 
returned to lower elevations before altitude illness has fully manifested. 
This practice has led to the true risks being underestimated, and (in 
our opinion) to an over-reliance on chemoprophylaxis to compensate 
for high-risk ascent profiles (see Table 2 of our article, adapted from 
Wilderness Medical Society guidelines[1,4]) rather than risk reduction 
through profile adjustment.[5] This increasing use of and/or reliance 
on chemoprophylaxis has also been described elsewhere, such as in 
Himalayan trekkers.[6] Furthermore, while there is good evidence 
that acetazolamide undoubtedly hastens acclimatisation (numbers 
needed to treat in the range of 3 - 8, depending on circumstance[6-8]), 
it cannot compensate for excessively rapid ascent.[9-12] For this reason, 
we have placed great emphasis on prevention, but wholeheartedly 
agree that acetazolamide has a strong role in moderate- to high-risk 
cases where acclimatisation alone is insufficient.[6,13] We reiterate 
our recommendation for first-time users to take a few test doses of 
acetazolamide prior to departure; while (as Dr Basnyat notes) the most 
common side-effect is severe paraesthesia/tingling/burning of the 
digits, it does help the user to identify the less common side-effects, 
which may be confused with AMS at altitude.[6]
With regard to treatment (as opposed to prophylaxis), it is worth 
noting that while acetazolamide is widely accepted and used, there are 
remarkably few examples of robust randomised studies supporting this 
practice.[4,14] However, we would re-emphasise our recommendation 
to follow the existing guidelines and initiate treatment in moderate 
to severe AMS.[4] For management of HAPE alone, acetazolamide 
and dexamethasone are indeed of questionable value, although the 
latter has been the subject of significant debate and appears in various 
guidelines. [4,15,16] While the brevity of our text and the accompanying 
cognitive aid may give the mistaken impression of a ‘shotgun’ approach, 
treatment must of course be selected in the context of the patient’s 
clinical condition, which may or may not include isolated AMS, HACE, 
HAPE, or any combination thereof. Dr Basnyat’s closing remark is 
apt: Lives could certainly be saved on Kilimanjaro by knowledgeable 
administration of acetazolamide, dexamethasone and other drugs. 
However, an ounce of prevention through conscientious mountaineering 
and adhering to safe ascent profiles is worth a pound of cure.
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